• SHARE

The first batch of BioNTech SE’s COVID-19 vaccine arrived in Taiwan on Thursday, after months of heated political and diplomatic wrangling and helped by the involvement of two of the world’s most important tech firms.

Taiwan has blamed China, which claims the island as its own territory, for nixing an original order from the German firm earlier this year — charges Beijing has angrily denied.

Taiwan’s government subsequently allowed major Apple Inc. supplier Foxconn as well as its high-profile billionaire founder Terry Gou, along with Taiwan Semiconductor Manufacturing Co., to negotiate on its behalf for the shot.

A $350 million deal for 10 million shots was inked in July, which will be donated to the government for distribution.

A cargo flight from Luxembourg carrying the made-in-Germany vaccines landed at Taiwan’s main international airport at Taoyuan, outside of Taipei, at 7 a.m., met on the tarmac by Health Minister Chen Shih-chung and Sophie Chang, the TSMC Charity Foundation’s chairwoman and Gou’s cousin.

In one further flourish of drama, China announced the exact arrival date of the vaccines on Wednesday, shortly before Chen began his daily news briefing.

The roughly 900,000 doses of the vaccine, jointly developed with Pfizer Inc., are expected to start being administered later this month.

Taiwan is getting the shots earlier than expected as a delay in regulatory approval of the shot for use in mainland China made a surplus available for the island. The vaccine is approved for use in Chinese-run Hong Kong and Macau.

While a relatively small domestic coronavirus outbreak is well under control in Taiwan, only around 5% of its 23.5 million people are fully vaccinated, though the government has millions of vaccines on order.

More than 10 million vaccine doses have arrived in Taiwan to date, split between Moderna Inc. and AstraZeneca PLC, while local developer Medigen Vaccine Biologics Corp.’s shots have also started to be administered.

A Taiwanese Buddhist group has also ordered 5 million doses from BioNTech.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)